165 related articles for article (PubMed ID: 36323578)
21. Multiple endocrine neoplasia type 2.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
[TBL] [Abstract][Full Text] [Related]
22. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J
Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997
[TBL] [Abstract][Full Text] [Related]
23. Multiple endocrine neoplasia type 2 (MEN 2).
Frank-Raue K; Raue F
Eur J Cancer; 2009 Sep; 45 Suppl 1():267-73. PubMed ID: 19775624
[No Abstract] [Full Text] [Related]
24. Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).
Lee JY; Kim SY; Jo KH; Mo EY; Kim ES; Kim HS; Han JH; Moon SD
Korean J Intern Med; 2022 Mar; 37(2):398-410. PubMed ID: 34905813
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
26. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
Lodish MB; Stratakis CA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
[TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
[TBL] [Abstract][Full Text] [Related]
28. Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms.
Guerin C; Romanet P; Taieb D; Brue T; Lacroix A; Sebag F; Barlier A; Castinetti F
Endocr Relat Cancer; 2018 Feb; 25(2):T15-T28. PubMed ID: 28874394
[TBL] [Abstract][Full Text] [Related]
29. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA; Pacini F; Robinson BG; Santoro M
J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408
[TBL] [Abstract][Full Text] [Related]
30. Multiple endocrine neoplasia type 2: clinical aspects.
Gimm O
Front Horm Res; 2001; 28():103-30. PubMed ID: 11443849
[No Abstract] [Full Text] [Related]
31. Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.
Wells SA
Endocr Relat Cancer; 2018 Feb; 25(2):T1-T13. PubMed ID: 29142004
[TBL] [Abstract][Full Text] [Related]
32. [Multiple endocrine neoplasia syndromes. Type 2].
Juodele L; Juozaityte E; Zindzius A; Pundzius J
Medicina (Kaunas); 2005; 41(4):281-94. PubMed ID: 15864001
[TBL] [Abstract][Full Text] [Related]
33. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
34. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes.
Kim IJ; Kang HC; Park JH; Ku JL; Lee JS; Kwon HJ; Yoon KA; Heo SC; Yang HY; Cho BY; Kim SY; Oh SK; Youn YK; Park DJ; Lee MS; Lee KW; Park JG
Clin Cancer Res; 2002 Feb; 8(2):457-63. PubMed ID: 11839664
[TBL] [Abstract][Full Text] [Related]
35. Multiple endocrine neoplasia type 2A: case report.
Păun DL; Poiană C; Petriş R; Radian S; Miulescu RD; Constantinescu G; Orban C
Chirurgia (Bucur); 2013; 108(6):900-3. PubMed ID: 24331334
[TBL] [Abstract][Full Text] [Related]
36. Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
Lebeault M; Pinson S; Guillaud-Bataille M; Gimenez-Roqueplo AP; Carrie A; Barbu V; Pigny P; Bezieau S; Rey JM; Delvincourt C; Giraud S; Veyrat-Durebex C; Saulnier P; Bouzamondo N; Chabbert M; Blin J; Mohamed A; Romanet P; Borson-Chazot F; Rohmer V; Barlier A; Mirebeau-Prunier D
Thyroid; 2017 Dec; 27(12):1511-1522. PubMed ID: 28946813
[TBL] [Abstract][Full Text] [Related]
37. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
38. Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation.
Ospina NS; Maraka S; Donegan D; Morris JC
Thyroid; 2017 Oct; 27(10):1332-1334. PubMed ID: 28747092
[TBL] [Abstract][Full Text] [Related]
39. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
40. Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
Qi XP; Zhao JQ; Fang XD; Lian BJ; Li F; Wang HH; Cao ZL; Zheng WH; Cao J; Chen Y
BMC Cancer; 2021 Apr; 21(1):369. PubMed ID: 33827484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
